Biotechnology · New Haven, Connecticut, United States
$15.79
+0.67% (+$0.11)2026-07-09
Smart-Money SignalNeutral · 52/100— Insiders are net buyers over 90 days ($4.2M, 14 buys vs 0 sales)
Revenue$212.0K
Net Income-$8.3M
EPS$-1.46
Market Cap$83.5M
Price Performance
Historical data including institutional events
Company Profile
S
Stephen Uden
CEO & Executive Director
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
- Founded
- 2018
- Employees
- 15
- Headquarters
- New Haven, Connecticut, United States
- Website
- www.rallybio.com
Peer ComparisonRevenue ($B)
▾Loading company sections...